Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence Endoscopy with Durvalumab-680LT and Nivolumab-800CW in Esophageal Cancer
NCT07196384Phase 1Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of Nivolumab-IRDye800CW and durvalumab-680LT in esophageal cancer (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Feasibility of dual tracer administration up to 14 months and Safety of dual tracer administration up to 14 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
Nivolumab-IRDye800CWdurvalumab-680LT
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT07196384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196384.